Journal
ORGANIC PROCESS RESEARCH & DEVELOPMENT
Volume 13, Issue 1, Pages 84-90Publisher
AMER CHEMICAL SOC
DOI: 10.1021/op800270e
Keywords
-
Categories
Ask authors/readers for more resources
Taranabant (1) is a cannabinoid-1 receptor (CB1R) inverse agonist that was recently in late-stage clinical development for the treatment of obesity. The previously employed synthesis exhibited a number of shortcomings for continuing development, and in this paper we report an improved synthesis of the target molecule that is suitable for large-scale implementation. Palladium-catalyzed amidation of an enol tosylate afforded a stereodefined tetrasubstituted enamide, and asymmetric hydrogenation thereof provided the target molecule.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available